Evaluation of the safety and efficacy of ABO non-identical apheresis platelets with reduced plasma transfusion
10.13303/j.cjbt.issn.1004-549x.2025.07.007
- VernacularTitle:ABO非同型少浆单采血小板输注的安全性及有效性评价
- Author:
Ronghua DIAO
1
,
2
;
Qianying RUAN
1
,
2
;
Lu BAI
3
;
Hong ZHANG
1
,
2
;
Zerong WANG
1
,
2
;
Lei FU
1
,
2
;
Shichun WANG
1
,
2
Author Information
1. Department of Blood Transfusion, First Affiliated Hospital of Army Medical University, Chongqing 400038, China
2. Chongqing Blood Center of the Chinese People's Liberation Army, Chongqing 400038, China
3. Department of Clinical Laboratory, First Affiliated Hospital of Army Medical University, Chongqing 400038, China
- Publication Type:Journal Article
- Keywords:
ABO blood group;
non-identical platelets;
non-identical platelets with reduced plasma;
platelet transfusion;
transfusion efficacy
- From:
Chinese Journal of Blood Transfusion
2025;38(7):909-914
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To evaluate the safety and efficacy of ABO non-identical platelets with reduced plasma (ABO-NPRP) transfusion in patients with hematological diseases. Methods: A retrospective analysis was conducted on 52 therapeutic doses of apheresis platelets with reduced plasma prepared at Chongqing Blood Center of the Chinese People's Liberation Army. The transfusion efficacy (24 h CCI) and the transfusion adverse reactions of these apheresis platelets were also observed in 35 patients with hematological diseases in First Affiliated Hospital of Army Medical University. Comparisons were made with a control group consisting of patients who received only identical apheresis platelets during the same period. Meanwhile, the effect of ABO-NPRP on the subsequent platelet transfusion efficacy was observed. Results: There was no statistically significant difference in PDW, MPV, and PLCR before and after the preparation of apheresis platelets with reduced plasma (P>0.05), while the difference in platelet count was statistically significant [(2.86±0.34)×10
per therapeutic dose vs (2.46±0.28)×10
per therapeutic dose, P<0.001]; there was no statistically significant difference in the 24 h CCI transfusion efficacy between conventional identical apheresis platelets and ABO-NPRP, with transfusion efficacy rates of 76.60% and 78.85%, respectively (P>0.05); there was no statistically significant difference in platelet transfusion efficacy between the group with ABO-NPRP and the group without ABO-NPRP (completely identical transfusion group), with transfusion efficacy rates of 77.78% and 75.25%, respectively (P>0.05). Conclusion: ABO-NPRP transfusion is safe, effective, demonstrating comparable efficacy to conventional identical transfusion. It can serve as an important complementary strategy to optimize the utilization of blood resources.
